Showing results (321-330 of 392) with videos related to
Sort By:
Pageof 40
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.International Journal of Cancer|February 10, 2016
Telomere dysfunction and chromothripsisAurélie Ernst, David T W Jones, Kendra K Maass, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.Haematologica|July 18, 2020
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphomaLorenz Thurner, Sylvia Hartmann, Moritz Bewarder, et al.The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.Pageof 40